MedTrace Logo

A Study to Investigate the Effect of Rifampicin on the Uptake and Breakdown of ACT-246475 in Healthy Subjects

NCT03814200 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2025-07-03

No results posted yet for this study

Summary

The study will investigate the effect of rifampicin on the uptake and breakdown of ACT-246475 in healthy subjects

Conditions

  • Healthy Subject

Interventions

DRUG

Saline

Single i.v. infusion of 100 mL saline 0.9% for 30 min

DRUG

ACT-246475

Single s.c. dose of 4 mg ACT-246475 in the thigh under fasting conditions

DRUG

Rifampicin

Single i.v. infusion of 600 mg rifampicin (100 mL) for 30 min

Sponsors & Collaborators

  • Viatris Innovation GmbH

    lead INDUSTRY

Principal Investigators

  • Clinical Trials · Viatris Innovation GmbH

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-01-03
Primary Completion
2019-02-12
Completion
2019-02-19
FDA Drug
Yes

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03814200 on ClinicalTrials.gov